IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On January 6, 2017, Ionis Pharmaceuticals, Inc. issued a press
release stating it expects to significantly improve upon its 2016
financial guidance for the fiscal year ending December 31, 2016.
A copy of the press release related to the announcement is
included with this report as Exhibit 99.1 and incorporated herein
by reference.
The information contained in Item 2.02 of this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed to be filed
for purpose of Section 18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) |
Exhibits.
|
99.1 |
Press Release dated January 6, 2017.
|
About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases. IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Recent Trading Information
IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) closed its last trading session up +0.74 at 47.83 with 3,104,583 shares trading hands.